Excel Venture Eyes $150 Million Second Life Sciences Fund

Excel Venture Management, a Boston company investing in life sciences technology companies, is shooting for $150 million in its second fund, a regulatory filing indicates. The company directs its investments toward health care IT and services, diagnostics and medical device firms, Among its 18 portfolio companies are Aileron Therapeutics Inc., Biocius Life Sciences Inc., BioTrove Inc., MedVentive Inc., PathoGenetiX Inc. and SpringLeaf Therapeutics Inc. Excel Venture launched its first fund with $125 million in 2009. That fund also focused on early to late-stage life sciences technology companies. At the time, Excel Managing Director Rick Blume said, “We are witnessing tremendous interest from non-traditional industries to incorporate life science technologies into their R&D programs. These companies represent a new source of partnering or acquisition exits for our investments."

Back to news